

# INDEX

Note: Page number followed by ‘f’ refer to figures and ‘t’ refer to tables.

- absolute breast cancer risk prediction tools, 308t
- absolute risk, 308
- accurate history, challenges to collecting
  - adoption or donor eggs/sperm, 291
  - estrangement from family, 291
  - incomplete family history information, 289–290
  - relatives or records are lost, 290
  - reported history is false, 292–293
- active and empathic listening, tools for, 456t
- active treatment, cancer patients in, 431–432
- activity limitations, 431–432
- acute myelogenous leukemia (AML), 253
- acute myeloid leukemia (AML), 32
- acute stress disorder/post-traumatic stress disorder, 436–437, 436t
- adaptive behavioral coping strategies, 446
- adaptive cognitive coping strategies, 445
- additional cancer therapies, 27
- additional emotional support
  - cancer syndrome support groups, 463–464
  - compassion satisfaction and compassion fatigue, 464–468
  - mental health referral, 461–463
- adoption or donor eggs/sperm, 291
- adoptive cell transfer (ACT) therapy, 22–24, 24f
- affective factors, 311
- affective responses, 443–444
- Affordable Care Act (ACA), 493
- affymetrix genome-wide human SNP array 6.0, 347f
- age/generational cohort, 441
- allele-specific oligonucleotide (ASO), 346–347
- allogeneic bone marrow transplants (BMTs), 212
- allogeneic transplant, 26
- all-trans retinoic acid (ATRA), 27
- alternative service delivery models for pre-test
  - education, 388
  - chatbots, 390
  - decision aids, 390
  - group pre-test counseling, 389
- American Association of Intellectual and Developmental Disabilities, 412
- American Cancer Society Screening Recommendations 2018, 47
- American College of Medical Genetics and Genomics (ACMG), 357, 377
- American Gastroenterological Association (AGA), 331
- American Society of Breast Cancer Surgeons (ASBrS) position statement, 331
- American Society of Human Genetics, 499
- ancestry, 282
  - and culture of origin, 440

- angiogenesis inhibitors (AGIs), 25
- antibody drug conjugates (ADCs), 25
- anticipated impact of results, 401
- anti-PD-L1/PD-1 therapy, 23
- anxiety disorders, 434–435
- anxiety-producing aspects of cancer genetic counseling, 443*t*
- apheresis, 26
- array technology, 351–352
- ataxia telangiectasia (AT)
  - clinical features, 218–219
  - diagnostic criteria, 218
  - genetic testing, 219
  - medical management, 219
  - syndrome subtypes, 219
  - tumor risks, 218
- ATM heterozygous carriers
  - cancer risks, 134
  - clinical features, 134
  - diagnostic criteria, 134
  - genetic testing, 134
  - medical management, 135
  - syndrome subtypes, 134
- autoimmune lymphoproliferative syndrome (ALPS), 220
  - clinical features, 220–221
  - diagnostic criteria, 220
  - genetic testing, 221
  - medical management, 221
  - syndrome subtypes, 221
  - tumor risks, 220
- autologous transplant, 26
- autonomy, 477–479
- autopsy report, 288
- autosomal dominant pattern of cancer, 294
- autosomal dominant with incomplete penetrance, 171
- Bannayan–Riley–Ruvalcaba syndrome (BRRS), 90, 154
- BAP1 tumor predisposition syndrome
  - clinical features, 175
  - diagnostic criteria, 174
  - genetic testing, 175
  - medical management, 175–176
  - syndrome subtypes, 175
  - tumor risks, 174–175
- baseline depression or anxiety, 402
- baseline mental health issues, 447–448
- Beckwith-Wiedemann syndrome
  - clinical features, 222
  - diagnostic criteria, 221–222
  - genetic testing, 223
  - medical management, 223–224
  - syndrome subtypes, 223
  - tumor risks, 222
- beneficence, 479
- benign dermatologic tumors, 177
- benign disease, 314–317
- benign prostatic hyperplasia (BPH), 316
- benign tumors, 8–9, 222, 260
  - associated with childhood cancer syndromes, 216–217*t*
  - excretion of hormones, 9
  - location and size, 9
  - and nontumor, 166, 167–170*t*
  - in rare tumor predisposition syndromes, 167–168*t*
- biallelic *BRCA1* pathogenic variants, 136
- biallelic *BRCA2* pathogenic variants, 136
- bilateral tumors or multiple tumor primaries
  - occur more frequently, 171
- biliary tract, 42–44
- bioethical principles and framework, 476
  - ethics of caring, 483–484
  - principle-based bioethics, 477–480
  - virtue ethics, 480–483
- bioethics, 477, 477*t*
- bipolar disease, 435–436, 435*t*
- bipolar I disease, 436
- bipolar II disease, 436
- Birt-Hogg-Dubé syndrome
  - clinical features, 177
  - diagnostic criteria, 176
  - genetic testing, 177–178
  - syndrome subtypes, 177
  - tumor risks, 176–177
- bispecific antibody T-cell engagers, 24
- blood cell development, 7*f*
- Bloom syndrome (BSyn)
  - clinical features, 225
  - diagnostic criteria, 224
  - genetic testing, 225
  - medical management, 226
  - syndrome subtypes, 225
  - tumor risks, 224–225

- bone marrow dysfunction, 253
- bone marrow transplant (BMT), 26, 235
- bone morphogenetic protein (BMP) pathway, 81*f*
- borderline personality disorder (BPD), 437, 438*t*
- brachytherapy, 18
- Brazilian founder pathogenic variant, 144
- BRCA1/2 carriers, 138
- BRCA1/2 genetic testing, 137
- BRCA2-associated gastric cancer, 113
- BRCAPRO model, 324
- breast, 314–315
  - anatomy, 130*f*
  - cancer risk, 319–320
- breast and gynecological cancer syndromes
  - anatomy, 129–131
  - ATM heterozygous carriers, 134–135
  - BRIP1 heterozygous carriers, 139–140
  - case examples, 158–161
  - CHEK2 pathogenic variant carriers, 140
  - clinical management issues, 131–132
  - documentation of exact tumor type, 132–133
  - hereditary breast and ovarian cancer syndrome (HBOC), 135–139
  - hereditary diffuse gastric cancer (HDGC), 141–142
  - Li-Fraumeni syndrome (LFS), 143–146
  - Lynch syndrome, 146–149
  - neurofibromatosis (NF1), 149–150
  - PALB2 heterozygous carriers, 150–151
  - Peutz-Jeghers syndrome (PJS), 151–152
  - PTEN hamartoma tumor syndrome (PHTS), 153–156
  - RAD51C heterozygous carriers, 156–157
  - RAD51D pathogenic variant carriers, 157–158
  - syndrome overlap, 133
  - timing of testing, 132
- Breast and Ovarian Analysis of Disease Incidence and Carrier Estimation Algorithm (BOADICEA), 326, 328
- breast and ovarian cancer syndrome (HBOC), 135
- Breast Cancer Risk Assessment Tool, 319
- Breast Cancer Surveillance Consortium (BCSC), 318
  - risk calculator, 319
- breast density, 317
- BRIP1 heterozygous carriers
  - cancer risks, 139
  - clinical features, 139
  - clinical recommendations, 139–140
  - diagnostic criteria, 139
  - genetic testing, 139
- café au lait (CALs), 191
- cancer, general signs and symptoms of, 2*t*
- cancer detection, 1–2, 3*t*
  - elusive premalignant cells, 3
  - imperfect or lack of screening methods, 3
  - lack of warning signs, 2
- cancer diagnosis, 278
- cancer family histories, 269, 270*t*
  - additional strategies and helpful hints, 283–286
- case examples, 299–303
- challenges to collecting accurate history
  - adoption or donor eggs/sperm, 291
  - estrangement from family, 291
  - incomplete family history information, 289–290
  - relatives or records are lost, 290
  - reported history is false, 292–293
- definition and purpose of the pedigree
  - assist with management recommendations, 275
  - clinical record and research tool, 276
  - determine need for and type of genetic testing, 275
  - disorder's inheritance pattern and other relatives at risk, 276
  - family dynamics and level of support, 277
  - identify cancer syndrome, 271–275
  - patient's emotional state, 277
  - patient's family stories, 277
  - uncover other syndromes, 275–276
- inclusivity, 270
- interpreting
  - features of inherited cancers, 293–295
  - high, moderate, low, and uncertain risk categories, 297–299
  - ways to classify family histories of cancer, 296–297
- key elements of comprehensive cancer history
  - ages and dates, 278–279
  - ancestry, 282
  - cancer diagnosis, 278
  - cancer risk factors, 282
  - cancer treatment and follow-up, 279
  - current surveillance practices, 280

- cancer family histories (*cont'd*)
  - presence of noncancerous features, 281
  - psychosocial factors, 282
  - relatives without diagnosis of cancer, 281
  - status and prognosis, 279–280
  - surgical procedures, 280–281
  - ways to confirm pedigrees, 287–289
- Cancer Gene (CaGene), 324, 327, 328
- CancerGene Connect, 324, 327
- cancer genetic counseling, 164*t*, 369, 429
  - additional suggestions for resolving ethical dilemmas, 490–491
  - anxiety-producing aspects of, 443*t*
  - bioethical principles and framework, 476
    - ethics of caring, 483–484
    - principle-based bioethics, 477–480
    - virtue ethics, 480–483
  - case examples, 468–472, 501–504
  - contextual information about patients
    - ethnocultural/social context, 439–442
    - family context, 437–439
    - mental health status, 433–437
    - physical health/cancer status, 430–433
  - four-box method, 488–489, 489*t*
  - patient reactions, coping responses, and risk perception, 442–446
  - providing additional emotional support
    - cancer syndrome support groups, 463–464
    - compassion satisfaction and compassion fatigue, 464–468
    - mental health referral, 461–463
  - standards of conduct for genetic counselors, 484–485
  - strategies for being an ethical counselor, 486–488
  - strategies for effective psychosocial genetic counseling
    - allow patients to express emotions, 457–458
    - ascertain the rationale behind questions and reactions, 457
    - ask rather than assume, 456–457
    - convey empathy, 454–455
    - deal with resistant patients, 458–459
    - employ active listening, 456
    - help patient with decisions and next action steps, 460
    - monitor patient reactions, 458
    - remain professional, 459–460
    - respect patient boundaries, 458
    - verbal and nonverbal cues, 456
  - strategies for providing psychosocial counseling
    - baseline mental health issues, 447–448
    - current emotional well-being, 446–447, 447*t*
    - emotional reactions and coping strategies, 448–449
    - family communication, 450–453
    - level of family support and communication, 453–454
    - timing issues and major life transitions and timing issues, 449–450
  - types of ethical dilemmas in
    - competing rights and roles, 493
    - confidentiality and privacy, 493–494
    - conflict of interest (COI), 494
    - consent and patient autonomy, 494–495
    - duty to recontact, 495–496
    - duty to warn, 496–497
    - inequality and access, 497–498
    - prenatal/preimplantation genetic testing, 498
    - testing children, 499
    - unintended results, 500–501
- cancer genetic counselors, 307, 455, 457, 459, 462–465
  - sample questions for, 448*t*
- cancer genetic programs, 495
- Cancer Genetics app, 332
- cancer genetic testing, 385*t*, 391
  - potential benefits and risks of, 379*t*
- cancer immunotherapy, types of, 20–21
- cancer patients
  - in active treatment, 431–432
  - with metastatic disease, 432–433
  - in remission, 432
- cancer pedigree quadrant system, 272*f*
- cancer risk assessment and risk models, 307
  - case examples, 333–335
  - genetics criteria
    - clinical genetic testing criteria, 330–331
    - criteria for referral for genetics consultation, 331–332
    - insurance-specific genetic testing criteria, 331
  - risk definitions
    - absolute risk, 308
    - empiric risk, 309, 309*t*

- genetic risk, 309
- odds ratio, 309
- relative risk, 308
- risk factors
  - benign disease, 314–317
  - exposures, 312–314
  - nondisease indicators of risk, 317–318
- risk modeling, 318
  - models that combine PV risk and penetrance information, 328
  - online risk assessment tools and calculators for clinicians, 328–329
  - patient-friendly risk assessment tools, 329–330
  - risk of developing cancer, 319–322
  - risk of hereditary disease, 322–328
- risk perception
  - changes in, 311–312
  - factors that contribute to, 310–311
- cancer risk factors, 282
- cancer syndrome
  - identifying, 271–275
  - support groups, 463–464
- cancer terminology, 4
  - cell type, 7
  - exceptions, 7–8
  - site of origin, 5
  - tissue type, 5–7
- cancer treatment, 14
  - additional cancer therapies, 27
  - chemotherapy, 18–19
  - and follow-up, 279
  - radiation therapy, 16–18
  - stem cell transplantation, 25–26
  - surgery, 15–16
  - targeted therapy, 19–25
- cancer vaccines, 24–25
- carcinomas, 5
- Carney–Stratakis syndrome, 196
- cascade testing, 400
- case examples, 158–161
  - cancer family histories, 299–303
  - cancer genetic counseling, 468–472
  - cancer genetic counseling and testing, 501–504
  - cancer risk assessment and risk models, 333–335
  - genetic testing technologies, 363–365
  - pediatric tumor predisposition syndromes, 262–265
  - pre-and post-test genetic counseling, 404–405
  - rare tumor predisposition syndromes, 204–207
  - special populations and special situations, 421–424
- case study, 30–33
- C-cell hyperplasia, 188
- CDKN2A* pathogenic variant, 327
- cell type, 7
- cellular differentiation, 10f
- chatbots, 390
- CHEK2 pathogenic variant carriers
  - cancer risks, 140
  - clinical features, 140
  - diagnostic criteria, 140
  - genetic testing, 140
  - medical management, 140
  - syndrome subtypes, 140
- chemical carcinogens, 28
- chemoprevention, 68, 84
- chemotherapy, 18–19
- childhood cancer syndromes, 214–216t
  - benign tumors associated with, 216–217t
- cholecystokinin (CCK), 110
- chronic pancreatitis, 110, 316
- Claus model, 320
- Clear Genetics, 390
- clinical diagnosis of depression, 433t
- clinical diagnostic criteria, 322–323
- clinical factors, 311
- clinical genetic counseling programs, 276
- clinical genetic testing companies, 387
- Clinical Genome Resource (ClinGen), 358, 358f
- clinical management issues, 131–132
- clinical record and research tool, 276
- ClinVar, 362, 363
- clonal hematopoiesis of indeterminate potential (CHIP), 500
- Cockayne syndrome (CS), 154
- Coffin Siris syndrome, 249–250
- cognitive factors, 311
- cognitive reactions, 444–445
- colon, 315
  - cancer risk, 320
  - and rectum, 44–45, 46f
- colonoscopies, 95
- colorectal cancer, 45–47
- Colorectal Cancer Risk Assessment Tool, 320
- colorectal polyps, types of, 48t

- colorectum, 46*f*
- colored eco-genetic relationship map (CEGRM), 453, 453*t*, 454*f*
- comparative genomic hybridization (CGH), 351
- compassion
  - fatigue, warning signs of, 464*t*
  - patients with, 482
- compassion satisfaction and compassion fatigue, 464–468
- comprehensive cancer history, key elements of
  - ages and dates, 278–279
  - ancestry, 282
  - cancer diagnosis, 278
  - cancer risk factors, 282
  - cancer treatment and follow-up, 279
  - current surveillance practices, 280
  - presence of noncancerous features, 281
  - psychosocial factors, 282
  - relatives without diagnosis of cancer, 281
  - status and prognosis, 279–280
  - surgical procedures, 280–281
- confidentiality, 387
  - and privacy, 493–494
- conflict of interest (COI), 388, 494
- congenital anomalies, 237
- congenital central hypoventilation syndrome (CCHS), 246
- congenital hypertrophy of the retinal pigment epithelium (CHRPE), 65, 71
- conscientiousness, 482
- consent and patient autonomy, 494–495
- constitutional epimutation, 59
- constitutional mismatch repair deficiency (CMMRD) syndrome, 56–58, 148, 226
  - clinical features, 227
  - diagnostic criteria, 226–227
  - genetic testing, 228
  - medical management, 228
  - syndrome subtypes, 227
  - tumor risks, 227
- constitutional mosaicism, 378
- contextual information about patients
  - ethnocultural/social context, 439–442
  - family context, 437–439
  - mental health status, 433–437
  - physical health/cancer status, 430–433
- contiguous gene deletion syndrome, 244
- convey empathy, 454–455
- coping and personality factors, 311
- coping resources, 401–402
- coping strategies, sample questions to assess, 449*t*
- copy number variants (CNVs), 341*f*
- Couch model, 325
- countertransference, 459
- Cowden syndrome (CS), 88
- CRA Health Risk Assessment Platform, 321, 329
- cryotherapy, 27
- Cultural Competency Toolkit, 413
- cumulative cancer risks, 86*t*
- curative/tumor removal surgery, 15
- current emotional well-being, 401, 446–447, 447*t*
- cyclothymia, 436
- cytoskeletal defects, 253
- Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4/CTLA4), 22
- data collection and risk assessment, 371–372
- death certificate, 288–289
- debulking surgery, 16
- decision aids, 390
- denaturing gradient gel electrophoresis (DGGE), 343–344
- dental anomalies in FAP, 65
- Denys-Drash syndrome (DDS), 258
- desmoid tumors, 64
- diagnosis and assessment of cancer, 4*t*
- diagnostic surgery, 15
- Diamond-Blackfan anemia (DBA), 228, 229
  - clinical features, 230
  - diagnostic criteria, 229
  - genetic testing, 230
  - medical management, 230
  - syndrome subtypes, 230
  - tumor risks, 229
- DICER1 tumor predisposition syndrome, 230
  - clinical features, 231
  - diagnostic criteria, 231
  - genetic testing, 232
  - medical management, 232
  - syndrome subtypes, 232
  - tumor risks, 231
- diethylstilbestrol (DES), 314
- diffuse gastric cancer, 96
- digestive tract, 37*f*
- discernment, 482

- disclosure session
  - content of, 392–393
  - genetic counseling strategies, 394–396
- disorder's inheritance pattern and other relatives at risk, 276
- DNA sequencing, 373
- ductal carcinomas, 130
- duodenal adenomatous polyps, 64
- duodenal polyps, 71
- duty to recontact, 495–496
- duty to warn, 496–497
- dyskeratosis congenita (DKC), 232, 234
  - clinical features, 234
  - diagnostic criteria, 234
  - genetic testing, 234
  - medical management, 235
  - syndrome subtypes, 234
  - tumor risks, 234
- effective psychosocial cancer genetic counseling, 455<sup>t</sup>
- effective psychosocial genetic counseling, strategies for
  - allow patients to express emotions, 457–458
  - ascertain the rationale behind questions and reactions, 457
  - ask rather than assume, 456–457
  - convey empathy, 454–455
  - deal with resistant patients, 458–459
  - employ active listening, 456
  - help patient with decisions and next action steps, 460
  - monitor patient reactions, 458
  - remain professional, 459–460
  - respect patient boundaries, 458
  - verbal and nonverbal cues, 456
- elusive premalignant cells, 3
- emotional closeness of the relationship, 439
- emotional reactions and coping strategies, 448–449
- emotion-focused coping strategies, 446
- empiric risk, 309, 309<sup>t</sup>
- employ active listening, 456
- endocrine glands, 42
- endometrial intraepithelial neoplasia (EIN), 317
- environmentally caused cluster of cancer, 296–297
- environmental risk factors, absence of, 295
- epidermoid cysts, 65
- epithelial ovarian cancer, 130
- esophageal cancer syndromes, 113
- esophagogastroduodenoscopy (EGD), 68
- esophagus, 39
- estrangement from family, 291
- ethical counselor, strategies for being, 486–488
- ethical dilemmas in cancer genetic counseling, types of
  - competing rights and roles, 493
  - confidentiality and privacy, 493–494
  - conflict of interest (COI), 494
  - consent and patient autonomy, 494–495
  - duty to recontact, 495–496
  - duty to warn, 496–497
  - inequality and access, 497–498
  - prenatal/preimplantation genetic testing, 498
  - testing children, 499
  - unintended results, 500–501
- ethics of caring, 483–484
- ethnocultural/social context, 439–442
- European consortium, 226
- exact tumor type, documentation of, 132–133
- excessive anxiety, 434
- exocrine pancreatic cancers, 42
- exome/genome testing, 374–375
- exposures, 312–314
  - and associated cancer risk, 313<sup>t</sup>
- express emotions, allow patients to, 457–458
- external beam radiation therapy (EBRT), 17
- extracolonic cancer in FAP, 65<sup>t</sup>
- eye disorders, 257
- eye manifestations, 260
- eye tumor, counseling about, 262–264
- facial/head anomalies, 237
- familial adenomatous polyposis (FAP), 62, 63, 67, 323
  - cancer risks, 64–65
  - diagnostic criteria, 63–64
  - extracolonic cancer in, 65<sup>t</sup>
  - genetic testing, 66–67
  - mechanism, 63
  - medical management, 68
  - other clinical features, 65
  - syndrome subtypes, 66



- familial atypical multiple mole melanoma
  - syndrome (FAMMM), 102*f*, 166, 178, 323
  - cancer risks, 103
  - clinical features, 103, 179
  - diagnostic criteria, 101–102, 178
  - genetic testing, 103–104, 179
  - mechanism, 101
  - medical management, 104, 179–180
  - syndrome subtypes, 103, 179
  - tumor risks, 178–179
- familial cluster of cancer, 296
- familial intestinal gastric cancer, 112
- familial lung cancer
  - clinical features, 180
  - diagnostic criteria, 180
  - genetic testing, 181
  - medical management, 181
  - syndrome subtypes, 180
  - tumor risks, 180
- familial medullary thyroid carcinoma (FMTC), 189
- Familial Risk Assessment—Breast and Ovarian Cancer (FRA-BOC), 329, 332
- family attachment, 438–439
- family communication, 450–453
- family context, 437–439
- family dynamics and level of support, 277
- family flexibility, 438
- family history questionnaire, use of, 286
- family obligations, 439
- family roles, 439
- family stories, 439
- FANCD1/BRCA2 Fanconi anemia, 237
- Fanconi anemia (FA), 235, 236
  - clinical features, 236–237
  - diagnostic criteria, 236
  - genetic testing, 237
  - heterozygotes, 237
  - medical management, 237–238
  - syndrome subtypes, 237
  - tumor risks, 236
- “female cancer,” 132
- female reproductive system/gynecological system, 131*f*
- fidelity, 482
- follow-up genetic counseling, 399–400
- founder pathogenic variant testing, 374
- four-box method, 488–489, 489*t*
- Frasier syndrome (FS), 258
- fumarate hydratase deficiency (FHD), 185
- Gail model, 319
- ganglioneuromas, 89
- gastric adenocarcinoma and proximal polyposis of the stomach (GAPPS), 64, 66, 112
- gastric (stomach) cancer, 47–49
- gastroesophageal junction (GEJ), 39
- gastrointestinal cancer syndromes
  - anatomy
    - biliary tract, 42–44
    - colon and rectum, 44–45
    - esophagus, 39
    - mouth and pharynx, 36–38
    - pancreas, 41–42
    - small intestine, 40
    - stomach, 39–40
- BRCA2-associated gastric cancer, 113
- colorectal cancer, 45–47
- esophageal cancer syndromes, 113
- familial adenomatous polyposis/
  - attenuated familial adenomatous polyposis, 62
  - cancer risks, 64–65
  - diagnostic criteria, 63–64
  - genetic testing, 66–67
  - mechanism, 63
  - medical management, 68
  - other clinical features, 65
  - syndrome subtypes, 66
- familial atypical multiple mole melanoma
  - syndrome
    - cancer risks, 103
    - diagnostic criteria, 101–102
    - genetic testing, 103–104
    - mechanism, 101
    - medical management, 104
    - other clinical features, 103
    - syndrome subtypes, 103
- familial intestinal gastric cancer, 112
- gastric adenocarcinoma and proximal polyposis of the stomach, 112
- gastric (stomach) cancer, 47–49
- hereditary diffuse gastric cancer syndrome, 96
  - cancer risks, 98
  - diagnostic criteria, 97–98
  - genetic testing, 99
  - mechanism, 96–97
  - medical management, 99–101
  - other clinical features, 98
  - syndrome subtypes, 99



- hereditary mixed polyposis syndrome, 90
  - cancer risks, 92
  - diagnostic criteria, 91
  - genetic testing, 92
  - mechanism, 91
  - medical management, 92
  - other clinical features, 92
  - syndrome subtypes, 92
- hereditary pancreatitis/familial
  - pancreatitis, 105
  - cancer risks, 109
  - diagnostic criteria, 109
  - genetic testing, 109
  - mechanism, 105–106
  - medical management, 110–111
  - other clinical features, 109
  - syndrome subtypes, 110
- juvenile polyposis syndrome (JPS), 79
  - cancer risks, 82
  - diagnostic criteria, 80–81
  - genetic testing, 83
  - mechanism, 80
  - medical management, 83–84
  - other clinical features, 82
  - syndrome subtypes, 83
- Li-Fraumeni syndrome, 111–112
- liver (hepato-)/gallbladder (choleangio-) cancer
  - syndromes, 113
- lynch syndrome, 51
  - cancer risks, 55–56
  - diagnostic criteria, 54–55
  - genetic testing, 58–60
  - mechanism, 52–54
  - medical management, 60–62
  - other clinical features, 56
  - syndrome subtypes, 56–58
- MUTYH*-associated polyposis, 68
  - cancer risks, 70–71
  - diagnostic criteria, 69–70
  - genetic testing, 72–73
  - mechanism, 69
  - medical management, 73
  - other clinical features, 71
  - syndrome subtypes, 72
- NTHL1 tumor syndrome, 73
  - cancer risks, 74
  - diagnostic criteria, 74
  - genetic testing, 75
  - mechanism, 74
  - medical management, 75
  - other clinical features, 74
  - syndrome subtypes, 75
- other rare noninherited gastrointestinal tract
  - syndromes, 113–114
- pancreatic cancer, 49–51
- pancreatic neuroendocrine tumor (NET)
  - syndromes, 113
- Peutz-Jeghers syndrome (PJS), 84
  - cancer risks, 85–86
  - diagnostic criteria, 85
  - genetic testing, 87
  - mechanism, 85
  - medical management, 87–88t
  - other clinical features, 86
  - syndrome subtypes, 87
- polymerase proofreading-associated polyposis
  - syndrome, 75
  - cancer risks, 77
  - diagnostic criteria, 76–77
  - genetic testing, 78–79
  - mechanism, 76
  - medical management, 79
  - other clinical features, 78
  - syndrome subtypes, 78
- PTEN hamartoma tumor syndromes, 88
  - cancer risks, 89
  - diagnostic criteria, 89
  - genetic testing, 90
  - mechanism, 89
  - medical management, 90
  - other clinical features, 89
  - syndrome subtypes, 90
- serrated polyposis syndrome, 92
  - cancer risks, 94–95
  - diagnostic criteria, 94
  - genetic testing, 95
  - mechanism, 93
  - medical management, 95–96
  - other clinical features, 95
  - syndrome subtypes, 95
- gender identity, 270
- gender/sexuality, 441
- gene-disease validity, 358
- gene panel testing, 370
- gene pathogenic variant status, 324–328
- generalized anxiety disorder, 434
  - symptoms of, 434t
- generalized juvenile polyposis, 239

- genesurance counseling, 381
- gene therapy, 25
- genetic analysis of tumor, 12–14
- genetic counseling
  - approaches, 500
  - and testing services, 497
- genetic counselors, 459
  - contracting, 396
  - establishing knowledge base, 396–397
  - patients primary language, 414–415
  - pre-test strategies for
    - facilitating decision making, 384–386
    - measuring success in informed consent, 386–387
  - standards of conduct for, 484–485
- genetic health care professionals, 388
- Genetic Information Non-Discrimination Act (GINA), 381, 381*t*, 493
- genetic risk, 309
- genetics, review of, 399
- genetics criteria
  - clinical genetic testing criteria, 330–331
  - criteria for referral for genetics consultation, 331–332
  - insurance-specific genetic testing criteria, 331
- genetics education, 372
- genetics information, 132
- genetic testing technologies, 249, 337, 500
  - allele-specific oligonucleotide (ASO), 346–347
  - array technology, 351–352
  - ataxia telangiectasia (AT), 219
  - ATM heterozygous carriers, 134
  - autoimmune lymphoproliferative syndrome, 221
  - BAP1 tumor predisposition syndrome, 175
  - Beckwith-Wiedemann syndrome, 223
  - Birt-Hogg-Dubé syndrome, 177–178
  - Bloom syndrome (BSyn), 225
  - BRIP1 heterozygous carriers, 139
  - case examples, 363–365
  - CHEK2 pathogenic variant carriers, 140
  - clinical issues, 357–360
    - conflicting interpretations, 362–363
    - variant classification, 361–362
    - variant reclassification, 362
  - denaturing gradient gel electrophoresis (DGGE), 343–344
  - determine need for and type of, 275
  - Diamond-Blackfan anemia, 230
  - DICER1 tumor predisposition syndrome, 232
  - Dyskeratosis congenita, 234
  - familial adenomatous polyposis/attenuated familial adenomatous polyposis, 66–67
  - familial atypical multiple mole melanoma syndrome, 103–104, 179
  - familial lung cancer, 181
  - Fanconi anemia, 237
  - Gorlin syndrome, 183
  - hereditary breast and ovarian cancer syndrome (HBOC), 137
  - hereditary diffuse gastric cancer (HDGC), 99, 142
  - hereditary leiomyomatosis renal cell cancer, 185
  - hereditary mixed polyposis syndrome, 92
  - hereditary pancreatitis/familial pancreatitis, 109
  - juvenile polyposis, 240
  - juvenile polyposis syndrome (JPS), 83
  - leukemia predisposition syndromes, 241–242
  - Li-Fraumeni syndrome (LFS), 144–145, 244
  - Lynch syndrome, 58–60, 148–149
  - methylation analysis, 352–354
  - multiple endocrine neoplasia, type 1, 187
  - multiple endocrine neoplasia, type 2, 189
  - multiplex ligase probe amplification (MLPA), 350–351
  - MUTYH*-associated polyposis, 72–73
  - neuroblastoma, familial, 246
  - neurofibromatosis, type 1, 192
  - neurofibromatosis, type 2, 194–195
  - next-generation sequencing (NGS), 348–350
  - NTHL1 tumor syndrome, 75
  - older technologies
    - linkage, 338
    - Maxam-Gilbert sequencing, 339
    - Sanger sequencing, 339
  - paired tumor germline analysis, 354–357
  - PALB2 heterozygous carriers, 151
  - paraganglioma-pheochromocytoma syndrome, 197–198
  - Peutz-Jeghers syndrome (PJS), 87, 152
  - polymerase proofreading-associated polyposis syndrome, 78–79
  - POT1 tumor predisposition syndrome, 198
  - prenatal/preimplantation, 498
  - protein truncation testing (PTT), 341–342

- psychological assessment throughout, 401–403
- PTEN hamartoma tumor syndrome (PHTS), 90, 155–156
- RAD51C heterozygous carriers, 157
- RAD51D pathogenic variant carriers, 158
- renal cell carcinoma papillary type 1, 200
- retinoblastoma, hereditary, 247–248
- rhabdoid tumor predisposition syndrome, 250
- Rothmund-Thomson syndrome, 252
- schwannomatosis, familial, 201
- serrated polyposis syndrome, 95
- Shwachman-Diamond syndrome, 253
- single nucleotide polymorphisms (SNPs), 344–346
- single-strand conformation polymorphism (SSCP), 343
- Southern blotting, 339–341
- transcriptome analysis, 354
- tuberous sclerosis complex (TSC), 256
- Von Hippel-Lindau syndrome, 203
- WT1-related syndrome, 258
- xeroderma pigmentosum, 262
- genetic test results, 288
- genome-wide association studies (GWAS), 345
- genomic rearrangement testing, 373
- germline methylation, 59
- germline pathogenic variants, 180
- glycosylases, 70
- gonadoblastoma tumors, 257
- Gorlin syndrome, 182
  - clinical features, 182–183
  - diagnostic criteria, 181–182
  - genetic testing, 183
  - medical management, 183
  - syndrome subtypes, 183
  - tumor risks, 182
- gradient gel electrophoresis, 344<sup>f</sup>
- group genetic counseling appointment, sample content of, 389<sup>t</sup>
- group pre-test counseling, 389
- group pre-test education, 389
- growth deficiency, 225
- guanine, 69
- gynecological cancer syndromes
  - breast and (*see* breast and gynecological cancer syndromes)
- gynecological malignancy risk in Lynch syndrome, 147<sup>t</sup>
- head and neck features, 225
- health care systems, 480
- Health Information Portability and Accountability Act (HIPAA), 493
- health-related decisions, 386
- hematologic and solid tumor, 214–216<sup>t</sup>
  - malignancies associated with childhood cancer syndromes, 214–216<sup>t</sup>
- hematopoietic cell transplants, 235
- hepatoblastoma, 64
- hepatocellular carcinoma and cholangiocarcinoma syndromes, 114<sup>t</sup>
- hereditary breast and ovarian cancer syndrome (HBOC), 322
  - cancer risks, 135–136
  - clinical features, 136
  - diagnostic criteria, 135
  - genetic testing, 137
  - medical management, 137–139
  - syndrome subtypes, 136
- hereditary cancer
  - genetic testing for, 369
  - syndrome, 296, 299<sup>f</sup>
- hereditary diffuse gastric cancer (HDGC)
  - syndrome, 96, 100<sup>f</sup>
    - cancer risks, 98, 141
    - clinical features, 141
    - diagnostic criteria, 97–98, 141
    - genetic testing, 99, 142
    - mechanism, 96–97
    - medical management, 99–101, 142
    - other clinical features, 98
    - syndrome subtypes, 99, 141
- hereditary disease, risk of, 322–328
- hereditary/familial pancreatic cancer, 50<sup>f</sup>
- hereditary gastrointestinal cancers, 35
- hereditary hemorrhagic telangiectasia (HHT), 84<sup>t</sup>, 239
- hereditary leiomyomatosis renal cell cancer
  - clinical features, 184–185
  - diagnostic criteria, 184
  - genetic testing, 185
  - medical management, 185
  - tumor risks, 184
- hereditary mixed polyposis syndrome, 90
  - cancer risks, 92
  - diagnostic criteria, 91
  - genetic testing, 92

- hereditary mixed polyposis syndrome (*cont'd*)
  - mechanism, 91
  - medical management, 92
  - other clinical features, 92
  - syndrome subtypes, 92
- hereditary pancreatic cancer, 323
- hereditary pancreatitis/familial pancreatitis, 105
  - cancer risks, 109
  - diagnostic criteria, 109
  - genetic testing, 109
  - mechanism, 105–106
  - medical management, 110–111
  - other clinical features, 109
  - syndrome subtypes, 110
- hereditary prostate cancer, 323
- heterozygous CDKN1B pathogenic variants, 186
- high categories, family at, 297
- high-risk patients, 430–431
- histological grades of tumors, 10*t*
- hormonal agents, 20
- hormones, 312–314
  - excretion of, 9
  - use/therapy, 280
- Hospital Ethical Review Boards, 492
- hospital summary notes, 288
- Hoyeraal Hreidarsson syndrome, 234
- human leukocyte antigens (HLAs), 26
- Huntington disease, 369
- hyperplastic/serrated polyps and mixed polyps, 70
- hyperthermic intraperitoneal chemotherapy (HIPEC), 27
- IBIS model, 325–326
- immune checkpoint blockade (ICB) therapy, 21–22
- immunodeficiency, 225
- immunohistochemistry (IHC) testing, 376
- immunotherapy, 20–25
- imperfect or lack of screening methods, 3
- indeterminate negative result, 377, 397
- inequality and access, 497–498
- inflammatory bowel disease (IBD), 315
- informed consent, 373–382, 488
  - documentation of, 382–383
  - measuring success in, 386–387
- initial encounter as post-test counseling, 421
- in-person disclosures, 391
- instrumental grief, 444
- integrity, 482
- intellectual disability (ID), patients with, 412–414
- internal radiation therapy, 18
- International Cancer of the Pancreas Screening Consortium (CAPS), 104
- intersex disorders, 257
- intraductal papillary mucinous neoplasms (IPMNs), 316
- intuitive grief, 444
- in vitro fertilization (IVF), 498
- juvenile polyposis syndrome (JPS), 79, 82*t*, 238–240
  - cancer risks, 82
  - clinical features, 239
  - coli, 239
  - diagnostic criteria, 80–81, 238
  - genetic testing, 83, 240
  - of infancy, 239
  - mechanism, 80
  - medical management, 83–84, 240
  - other clinical features, 82
  - syndrome subtypes, 83, 239
  - tumor risks, 239
- kindness, 483
- KLLN pathogenic variants, 154
- learning disabilities, 225
- Leigh syndrome, 196–197
- leukemia predisposition syndromes
  - clinical features, 241
  - diagnostic criteria, 240
  - genetic testing, 241–242
  - medical management, 242
  - syndrome subtypes, 241
  - tumor risks, 241
- leukemias, 6
- level of family support and communication, 453–454
- Lhermitte-Duclos disease (LDD), 90, 154
- Li-Fraumeni-like (LFL) syndromes, 143*t*, 242*t*
- Li-Fraumeni syndrome (LFS), 111–112, 143*t*, 172, 242*t*, 276, 322, 326
  - cancer risks, 143–144
  - clinical features, 144, 244
  - diagnostic criteria, 143, 242–243
  - genetic testing, 144–145, 244
  - medical management, 145–146, 244–245

- syndrome subtypes, 144, 244
- tumor risks, 243
- liquid biopsies, 355–357, 356*f*
- liver functions, 43
- liver (hepato-)/gallbladder (choleangio-) cancer syndromes, 113
- lobular carcinoma in situ (LCIS), 314–315
- loss of control, 444
- low-penetrance pathogenic variants, 244
- low penetrant RB, 247
- low risk categories, family at, 298–299
- lymph nodes and vessels, 130
- lymphomas, 6
- Lynch/hereditary colon cancer, 326–327
- Lynch syndrome, 51, 323
  - cancer risks, 55–56, 57*t*, 146, 147*t*
  - clinical features, 148
  - diagnostic criteria, 54–55, 146
  - genes, 226
  - genetic testing, 58–60, 148–149
  - gynecological malignancy risk in, 147*t*
  - mechanism, 52–54
  - medical management, 60–62, 149
  - other clinical features, 56
  - syndrome subtypes, 56–58, 148
- major life transitions, 450*t*
- malignant cells play tricks, 14
- malignant melanoma, 101
  - lifetime risk of, 179
- malignant peripheral nerve sheath tumors (MPNSTs), 191
- maternal imprinting, cases of, 247
- Maxam-Gilbert sequencing, 339
- medical management options, 392–393
- melanomas, 178
  - counseling about, 204–205
  - risk, 318, 321
- MelaPRO model, 327
- MELPREDICT model, 328
- MEN2B, 188, 189
- menopausal hormone therapy, 313
- mental health challenges, patients with, 411–412
- mental health referral, 461–463, 461*t*
- mental health status
  - acute stress disorder/post-traumatic stress disorder, 436–437
  - anxiety disorders, 434–435
  - bipolar disease, 435–436
  - borderline personality disorder (BPD), 437
  - depressive disorders, 433
- mesothelioma, counseling about, 204–205
- metastatic disease, cancer patients with, 432–433
- metastatic uveal melanoma, 175
- methylation analysis, 352–354
- microarray-based comparative genomic hybridization, 353*f*
- microsatellite instability (MSI), 376
- mixed types, 6
- MMR*Predict*, 327
- MMR*Pro* model, 327
- mode of results disclosure, 391–392
- moderate categories, family at, 297–298
- molecular studies, 13–14
- molecular subtypes of colorectal cancer, 13*f*
- moles, 315
- monitor patient reactions, 458
- mosaicism, 378
- mosaic results, 378–379
- mouth and pharynx, 36–38
- mucocutaneous lesions, 86
- Muir-Torre syndrome (MTS), 58, 148
- multidimensional measure of informed choice (MMIC), 387
- multifocal or bilateral cancers, 295
- multigene panel testing (MGPT), 374
- multiple endocrine neoplasia
  - type 1
    - clinical features, 186
    - diagnostic criteria, 185
    - genetic testing, 187
    - medical management, 187
    - syndrome subtypes, 186–187
    - tumor risks, 186
  - type 2, 187–190
    - clinical features, 188
    - diagnostic criteria, 188
    - genetic testing, 189
    - medical management, 189–190
    - syndrome subtypes, 188–189
    - tumor risks, 188
- multiple primary cancers, 295
- multiplex ligase probe amplification (MLPA), 350–351, 352*f*
- multiplex-ligation-dependent probe amplification (MLPA), 341

- Münchhausen syndrome, 293
- MUTYH*-associated polyposis, 68
  - cancer risks, 70–71
  - diagnostic criteria, 69–70
  - genetic testing, 72–73
  - mechanism, 69
  - medical management, 73
  - other clinical features, 71
  - syndrome subtypes, 72
- MUTYH* polyposis, 71*t*–73*t*
- myelodysplastic syndrome (MDS), 212, 229, 236
- myeloma, 6
- myeloproliferative neoplasms, 7*t*
- Myriad II, 324–325
- nasopharynx, 38
- National Cancer Institute (NCI), 319
- National Comprehensive Cancer Network (NCCN), 330–332, 370
- National Institutes of Health (NIH), 361
- National Institutes of Mental Health (NIMH), 433
- National Quality Forum (NQF), 386
- National Society of Genetic Counselors (NSGC), 270, 271
  - code of ethics, 485*t*
- negative results, 398
- neoplasm, 5
- neuroblastic tumors, 245
- neuroblastoma, familial
  - clinical features, 246
  - diagnostic criteria, 245
  - genetic testing, 246
  - medical management, 246
  - syndrome subtypes, 246
  - tumor risks, 245
- neuroblastomas, 245
- neuroectodermal tumors, 6
- neurofibromatosis (NF1), 149–150
  - cancer risks, 150
  - diagnosis, 149
  - medical management, 150
- type 1
  - clinical features, 191
  - diagnostic criteria, 190
  - genetic testing, 192
  - medical management, 192
  - syndrome subtypes, 191–192
  - tumor risks, 190–191
- type 2, 192–195
  - clinical features, 194
  - diagnostic criteria, 192–193
  - genetic testing, 194–195
  - medical management, 195
  - syndrome subtypes, 194
  - tumor risks, 194
- neurologic problems, 260
- newly diagnosed cancer patients, 431
- next-generation sequencing (NGS), 348–350, 349*f*
  - methods, 244
  - technology, 374
- Nicolaides Baraitser syndrome, 250
- NIH Breast Cancer Risk Assessment Tool, 329
- noncancerous features, presence of, 281
- nondisease indicators of risk, 317–318
- non-genetics professional, 332–333
- non-Hodgkin lymphoma, 227
- nonmaleficence, 479
- nonmalignant features, 295
- NTHL1 tumor syndrome, 73
  - cancer risks, 74
  - diagnostic criteria, 74
  - genetic testing, 75
  - mechanism, 74
  - medical management, 75
  - other clinical features, 74
  - syndrome subtypes, 75
- occupations or occupational exposure, 29–30*t*
- odds ratio (OR), 309
- oligonucleotide probes, 346
- oncolytic virus (OV) therapy, 24
- online risk assessment tools and calculators for clinicians, 328–329
- Ontario Family History Assessment Tool (FHAT), 325
- oral cavity and pharynx, 38, 38*f*
- oral contraceptives (OCs), 312–313
- oral systemic therapy, 18
- ordinary moral standards, 481
- ovarian cancer risk, 321
- ovary, 316
- paired tumor germline analysis, 354–357
- paired tumor/germline testing, 375

- PALB2 heterozygous carriers
  - cancer risks, 150
  - clinical features, 150
  - diagnostic criteria, 150
  - genetic testing, 151
  - medical management, 151
  - syndrome subtypes, 150
- palliative surgery, 16
- PancPro, 322
- pancreas, 41–42, 316
- pancreatic cancer, 49–51
- Pancreatic Cancer Action Network, 321
- pancreatic cancer risk, 321–322
- pancreatic dysfunction, 253
- pancreatic exocrine function, 110
- pancreatic intraepithelial neoplasia (PanIN), 316
- pancreatic neuroendocrine tumor (NET)
  - syndromes, 113
- pancreatitis, 105
- panic disorders, 435
- paraganglioma–pheochromocytoma syndrome
  - clinical features, 196
  - diagnostic criteria, 195
  - genetic testing, 197
  - medical management, 197–198
  - syndrome subtypes, 196–197
  - tumor risks, 195–196
- paragangliomas, 150
  - subtype 1, 197
  - subtype 2, 197
  - subtype 3, 197
  - subtype 4, 197
- paraganglioma syndrome (PGL), 194, 195
- Pate v. Threlkel*, 496
- pathogenic variant (PV), 318, 376
- pathology report, 287–288
- patient confidentiality, respecting, 486–487
- patient-friendly risk assessment tools, 329–330
- patient privacy, respecting, 487
- patient reactions
  - coping responses, and risk perception, 442–446
  - to results, 397–398
- patients
  - decisions, respecting, 487
  - emotional state, 277
  - at end of life, 410–411
  - family stories, 277
  - with intellectual disability, 412–414
  - with mental health challenges, 411–412
  - primary language, 414–415
- pediatric cancer genetic counseling, 209, 210
- pediatric tumor predisposition syndromes, 213
  - ataxia telangiectasia (AT), 218–219
  - autoimmune lymphoproliferative syndrome, 219–221
  - Beckwith-Wiedemann syndrome, 221–224
  - benign tumors associated with childhood cancer syndromes, 216–217*t*
  - Bloom syndrome (BSyn), 224–226
  - case examples, 262–265
  - constitutional mismatch repair deficiency syndrome, 226–228
  - counseling issues, 209–213
  - Diamond-Blackfan anemia (DBA), 228–230
  - DICER1 tumor predisposition syndrome, 230–232
  - dyskeratosis congenita, 232–235
  - Fanconi anemia, 235–238
  - hematologic and solid tumor malignancies associated with childhood cancer syndromes, 214–216*t*
  - juvenile polyposis syndrome (JPS), 238–240
  - leukemia predisposition syndromes, 240–242
  - Li-Fraumeni syndrome, 242–245
  - neuroblastoma, familial, 245–246
  - retinoblastoma, hereditary, 246–248
  - rhabdoid tumor predisposition syndrome, 248–250
  - Rothmund-Thomson syndrome, 250–252
  - Shwachman-Diamond syndrome, 252–253
  - tuberous sclerosis complex (TSC), 254–256
  - WT1-related syndrome, 256–258
  - xeroderma pigmentosum, 259–262
- pedigree, definition and purpose of
  - assist with management recommendations, 275
  - clinical record and research tool, 276
  - determine need for and type of genetic testing, 275
  - disorder's inheritance pattern and other relatives at risk, 276
  - family dynamics and level of support, 277
  - identify cancer syndrome, 271–275
  - patient's emotional state, 277
  - patient's family stories, 277
  - uncover other syndromes, 275–276
- pedigree construction, questions during, 273–274*t*



- PENN II model, 325
- personal and family history information,
  - updating, 400
- personalized cancer therapy, 388
- Peutz-Jeghers syndrome (PJS), 84, 151–152
  - cancer risks, 85–86, 151–152
  - clinical features, 152
  - diagnostic criteria, 85, 151
  - genetic testing, 87, 152
  - mechanism, 85
  - medical management, 87–88*t*, 153
  - other clinical features, 86
  - syndrome subtypes, 87, 152
- pheochromocytoma syndrome (PCC), 194, 195
- phobia-related disorders, 434
- photon particles, 17
- physical health/cancer status, 430–433
- physical symptoms, 431
- polyaromatic hydrocarbons (PAH), 28
- polygenic risk score (PRS) testing, 317, 345, 346, 375
- polymerase proofreading-associated polyposis syndrome, 75
  - cancer risks, 77
  - diagnostic criteria, 76–77
  - genetic testing, 78–79
  - mechanism, 76
  - medical management, 79
  - other clinical features, 78
  - syndrome subtypes, 78
- polyps, 315
- positive CDH1 result, counseling about reactions
  - to, 468–470
- positive results, 376–377, 397, 398
- positive TP53 result, counseling about reactions
  - to, 470–472
- post-traumatic stress disorder (PTSD), 437*t*
- POT1 tumor predisposition syndrome
  - clinical features, 198
  - diagnostic criteria, 198
  - genetic testing, 198
  - medical management, 198–199
  - syndrome subtypes, 198
  - tumor risks, 198
- pre-and post-test genetic counseling, 369–370
  - alternative service delivery models for pre-test
    - education, 388
    - chatbots, 390
    - decision aids, 390
    - group pre-test counseling, 389
  - case examples, 404–405
  - confidentiality, 387
  - follow-up genetic counseling, 399–400
  - genetic counselors
    - contracting, 396
    - establishing knowledge base, 396–397
  - genetic health care professionals, 388
  - negative results, 398
  - patient reactions to results, 397–398
  - positive results, 398
  - pre-test strategies for genetic counselors
    - facilitating decision making, 384–386
    - measuring success in informed consent, 386–387
  - psychological assessment throughout genetic testing process, 401–403
  - traditional post-test genetic counseling, 390
    - content of disclosure session, 392–393
    - disclosure session genetic counseling strategies, 394–396
    - mode of results disclosure, 391–392
  - traditional pre-test genetic counseling session
    - basis for decision making, 371–372
    - documentation of informed consent, 382–383
    - genetic test results disclosure, 383–384
    - informed consent, 373–382
  - use of samples for research, 387–388
  - VUS results, 399
- preimplantation genetic testing (PGT), 498
- PREMM5 model, 327
- prenatal/preimplantation genetic testing, 498
- pre-test education, alternative service delivery
  - models for, 388
  - chatbots, 390
  - decision aids, 390
  - group pre-test counseling, 389
- pre-test genetic counseling session, 371
- pre-test informed consent, 371
- pre-test strategies for genetic counselors
  - facilitating decision making, 384–386
  - measuring success in informed consent, 386–387
- primary cancer or recurrence, 8
- primitive neuroectodermal tumors (PNETs), 190
- principle-based bioethics
  - autonomy, 477–479
  - beneficence, 479

- nonmaleficence, 479
- principle of justice, 479–480
- principle of justice, 479–480
- professional genetics organizations, 499*t*
- Programmed Death 1 (PD-1/PD1), 22
- prolactinomas, 186
- prophylactic total gastrectomy (PTG), 142
- prostate, 316–317
- prostatic intraepithelial neoplasia (PIN), 316
- protein truncation testing (PTT), 341–342
- Proteus syndrome, 154
- proton beam therapy, 17
- psychological assessment throughout genetic testing process, 401–403
- psychological counseling services, 461
- psychological/emotional education, 372
- psychosocial counseling, strategies for providing
  - baseline mental health issues, 447–448
  - current emotional well-being, 446–447, 447*t*
  - emotional reactions and coping strategies, 448–449
- family communication, 450–453
- level of family support and communication, 453–454
- timing issues and major life transitions and timing issues, 449–450
- PTEN hamartoma tumor syndrome (PHTS), 155–156*t*, 322, 323*t*
  - cancer risks, 154
  - clinical features, 154
  - diagnostic criteria, 153
  - genetic testing, 155–156
  - syndrome subtypes, 154
- PTEN hamartoma tumor syndromes, 88, 326
  - cancer risks, 89
  - diagnostic criteria, 89
  - genetic testing, 90
  - mechanism, 89
  - medical management, 90
  - other clinical features, 89
  - syndrome subtypes, 90
- PTEN risk calculator, 326
- pulmonary lesion, counseling about, 264–265
- RAD51C heterozygous carriers
  - cancer risks, 157
  - clinical features, 157
  - clinical recommendations, 157
  - diagnostic criteria, 156
  - genetic testing, 157
  - syndrome subtypes, 157
- RAD51D pathogenic variant carriers
  - cancer risks, 157
  - clinical features, 158
  - diagnostic criteria, 157
  - genetic testing, 158
  - medical management, 158
  - syndrome subtypes, 158
- radial ray anomalies, 236–237
- radiation therapy, 16
  - types of, 17–18
- rare noninherited gastrointestinal tract syndromes, 113–114
- rare tumor predisposition syndromes, 165–166*t*, 167–168*t*
  - autosomal dominant with incomplete penetrance, 171
  - BAP1 tumor predisposition syndrome, 174–176
  - benign tumors and nontumor, 166, 167–170*t*
  - bilateral tumors or multiple tumor primaries occur more frequently, 171
  - Birt-Hogg-Dubé syndrome, 176–178
  - case examples, 204–207
  - clinical features of selected, 173
  - counseling issues with, 171–173
  - familial atypical multiple mole melanoma syndrome, 178–180
  - familial lung cancer, 180–181
  - Gorlin syndrome, 181–183
  - hereditary leiomyomatosis renal cell cancer, 183–185
  - multiple endocrine neoplasia, Type 1, 185–187
  - multiple endocrine neoplasia, Type 2, 187–190
  - neurofibromatosis, Type 1, 190–192
  - neurofibromatosis, Type 2, 192–195
  - nontumor features in, 168–170*t*
  - paraganglioma–pheochromocytoma syndrome, 195–198
  - POT1 tumor predisposition syndrome, 198–199
  - presence of tumor in proband, 164–166
  - renal cell carcinoma papillary type 1, 199–200
  - schwannomatosis, familial, 200–202
  - unusual and/or uncommon cancers, 163–164
  - Von Hippel-Lindau syndrome, 202–204
- rationale behind questions and reactions, 457
- reconstructive surgery, 16

- recurrent acute pancreatitis/chronic pancreatitis
  - genetic risk factors, 107–108*t*
- reduced fertility, 225, 237
- relative risk (RR), 308
- religion/spirituality, 440–441
- renal cell carcinoma papillary type 1
  - clinical features, 199
  - diagnostic criteria, 199
  - genetic testing, 200
  - medical management, 200
  - syndrome subtypes, 199
  - tumor risks, 199
- renal disorders, 257
- reproductive risks, 257
- resistant patients, deal with, 458–459
- resource identification, 393
- respectfulness, 483
- respect patient boundaries, 458
- retinoblastoma, hereditary
  - clinical features, 247
  - diagnostic criteria, 246–247
  - genetic testing, 247–248
  - medical management, 248
  - syndrome subtypes, 247
  - tumor risks, 247
- retinoblastoma protein (pRB), 101
- retinoid agents, 27
- Revesz syndrome, 234
- rhabdoid tumor predisposition syndrome (RTPS)
  - clinical features, 249
  - diagnostic criteria, 249
  - genetic testing, 250
  - medical management, 250
  - syndrome subtypes, 249–250
  - tumor risks, 249
- risk factors for cancer, 28, 29*t*
- risk modeling, 318
  - models that combine PV risk and penetrance information, 328
  - online risk assessment tools and calculators for clinicians, 328–329
  - patient-friendly risk assessment tools, 329–330
  - risk of developing cancer, 319–322
  - risk of hereditary disease, 322–328
- risk perception
  - changes in, 311–312
  - factors that contribute to, 310–311
- risk-reducing bilateral mastectomy (RRBM), 138, 146
- risk-reducing bilateral salpingo-oophorectomy (RRBSO), 138
- risk-reducing surgery, 16, 156
- RNA testing, 375
- Rothmund-Thomson syndrome (RTS), 250
  - clinical features, 251–252
  - diagnostic criteria, 250–251
  - genetic testing, 252
  - medical management, 252
  - syndrome subtypes, 252
  - tumor risks, 251
- Safer v. Estate of Pack*, 496–497
- Sanger sequencing, 339
- sarcomas, 5–6
- schwannomatosis, familial, 200
  - clinical features, 201
  - diagnostic criteria, 200
  - genetic testing, 201
  - medical management, 201–202
  - syndrome subtypes, 201
  - tumor risks, 200–201
- secretin-stimulated pancreatic bicarbonate secretion testing, 110
- segmental neurofibromatosis, 191, 194
- segmental schwannomatosis, 201
- selective internal radiation therapy (SIRT), 18
- sequencing by synthesis (SBS), 348
- serrated polyposis syndrome, 92
  - cancer risks, 94–95
  - diagnostic criteria, 94
  - genetic testing, 95
  - mechanism, 93
  - medical management, 95–96
  - other clinical features, 95
  - syndrome subtypes, 95
- serrated polyps, 93, 94*t*
- serum trypsinogen, 110
- service delivery models (SDMs), 388
- sex cord tumors with annular tubules (SCTAT), 152
- shared decision making (SDM), 384, 386, 387
- Shwachman-Diamond syndrome (SDS), 252
  - clinical features, 253
  - diagnostic criteria, 252
  - genetic testing, 253

- medical management, 253
- syndrome subtypes, 253
- tumor risks, 253
- signal transduction inhibitors, 20
- signet ring cell cancer (SRCC), 101
- single nucleotide polymorphisms (SNPs), 317–318, 344–346
- single nucleotide variants (SNVs), 345
- single-site analysis, 374
- single-strand conformation polymorphism (SSCP), 343
- site of origin, 5
- Skeletal anomalies, 251
- skin, 315
  - changes, 225
  - complexion, 318
  - pigmentation, 237
- small cell lung cancer, counseling about, 205–207
- small intestine, 40, 41f
- social anxiety disorders, 435
- social identity and intersectionality, 442
- social isolation, 432
- somatic mosaicism, 378
- somatic testing, 376
- Southern blotting, 339–341
- special populations, counseling for, 409
  - patients at end of life, 410–411
  - patients primary language, 414–415
  - patients with intellectual disability, 412–414
  - patients with mental health challenges, 411–412
  - transgender and gender diverse (TGD), 415–417
- SPIKES model, 419
- sporadic forms of cancer, 297
- sporadic juvenile polyps, 81
- staging, 11–12
  - surgery, 15
- standardized pedigree nomenclature, 284
- stem cells, 26
  - transplantation, 25–26
- stomach, 39–40
- surgery of cancer treatment
  - curative/tumor removal surgery, 15
  - debulking surgery, 16
  - diagnostic surgery, 15
  - reconstructive surgery, 16
  - risk-reducing surgery, 16
  - staging surgery, 15
- surgical procedures, 280–281
- syndrome overlap, 133
- tamoxifen, 20
- targeted therapy, 19–25
- T-cell receptor (TCR), 22
- telephone disclosures, 391
- testing
  - benefits of, 379–380
  - children, 499
  - risks of, 380–381
  - timing of, 132
- thermal therapy, 27
- 13q deletion syndrome, 247
- thyroid cancer, 64
- thyroid-stimulating hormone (TSH), 18
- timing issues and major life transitions and timing issues, 449–450
- timing of testing, 132
- tissue type, 5–7
- Title VI of the Civil Rights Act of 1964, 414
- TNM cancer staging of medullary thyroid carcinoma, 12f
- traditional post-test genetic counseling, 390
  - content of disclosure session, 392–393
  - disclosure session genetic counseling strategies, 394–396
  - mode of results disclosure, 391–392
- traditional pre-test genetic counseling
  - session, 372
  - basis for decision making, 371–372
  - documentation of informed consent, 382–383
  - genetic test results disclosure, 383–384
  - informed consent, 373–382
- transcriptome analysis, 354
- transference, 459
- transgender and gender diverse (TGD), 415–417
- true negative result, 378, 398
- trustworthiness, 483
- tuberous sclerosis (TS), 255
- tuberous sclerosis complex (TSC)
  - clinical features, 255
  - diagnostic criteria, 254
  - genetic testing, 256
  - medical management, 256
  - syndrome subtypes, 255–256
  - tumor risks, 254–255

- tumor classification
  - benign tumors, 8–9
  - genetic analysis of the tumor, 12–14
  - staging, 11–12
  - tumor grading, 10–11
- tumor genomic testing, 375
- tumor grading, 10–11
- tumor mutational burden (TMB), 54
- tumor sequencing, 376
- Turcot syndrome, 58, 148
- type 1 papillary renal tumors, 199
- Tyrer-Cuzick model, 319, 325–326
- unanticipated results, counseling about
  - addressing unknown cancer risk, 419–421
  - initial encounter as post-test counseling, 421
  - transgender and gender diverse (TGD), 415–417
  - unexpected high-penetrance pathogenic variants, 417–419
- unexpected high-penetrance pathogenic variants, 417–419
- unintended results, 500–501
- unknown cancer risk, addressing, 419–421
- unusual and/or uncommon cancers, 163–164
- uterine, 317
- variant classification, 361–362
- variant curation expert panels (VCEPS), 362
- variant reclassification, 362
- variants of uncertain significance (VUS), 264, 362, 377, 398, 399
- veracity, 483
- verbal and nonverbal cues, 456
- verbal confirmation, 287
- vestibular schwannoma, 194
- virtue ethics, 480–483
- Von Hippel-Lindau (VHL) syndrome, 166, 172, 297
  - clinical features, 203
  - diagnostic criteria, 202
  - genetic testing, 203
  - medical management, 204
  - syndrome subtypes, 203
  - tumor risks, 202–203
- WAGR syndrome, 258
- warning signs, lack of, 2
- whole-genome sequencing (WGS), 374
- wisdom, 483
- WT1-related syndrome
  - clinical features, 257
  - diagnostic criteria, 257
  - genetic testing, 258
  - medical management, 258
  - syndrome subtypes, 258
  - tumor risks, 257
- xeroderma pigmentosum (XP), 259, 260
  - clinical features, 260
  - diagnostic criteria, 259
  - genetic testing, 262
  - medical management, 262
  - and related disorders, 261*t*
  - syndrome subtypes, 260–262
  - and trichothiodystrophy, 262
  - tumor risks, 260